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Summary 
Analysis of the cDNA encoding murine interleukin (IL) 17 (cytotoxic T lymphocyte associated 
antigen 8) predicted a secreted protein sharing 57% amino acid identity with the protein pre- 
dicted from ORF13, an open reading frame ofHerpesvirus saimiri.  Here we report on the clon- 
ing of human IL-17 (hlL-17), the human counterpart ofmurine IL-17. hlL-17 is a glycopro- 
tein  of 155  amino  acids  secreted  as  an  homodimer  by  activated  memory  CD4  +  T  cells. 
Although devoid of direct effects on cells of hematopoietic origin, hlL-17 and the product of 
its viral counterpart, Olq.F13, stimulate epithelial, endothelial, and fibroblastic cells to secrete 
cytokines such as IL-6, IL-8, and granulocyte--colony-stimulating factor, as well as prostaglan- 
din E2.  Furthermore, when cultured in the presence of hlL-17, fibroblasts could sustain  the 
proliferation of CD34 + hematopoietic progenitors and their preferential maturation into neu- 
trophils. These observations suggest that hlL-17 may constitute (a) an early initiator of the T 
cell-dependent inflammatory reaction; and (b) an element of the cytokine network that bridges 
the immune system to hematopoiesis. 
T  lymphocytes produce an array of small  proteins  that 
are involved in cell growth, inflammation, immunity, 
differentiation, and repair. These protein mediators referred 
to as cytokines are not produced constitutively by T  cells, 
but rather are induced after receptor-mediated T  cell acti- 
vation  (1,  2).  Murine  cytotoxic T  lymphocyte associated 
antigen-8 (mCTLA8) 1, a cDNA previously cloned by lq.ou- 
vier  et  al.  (3)  from  a  T  cell  subtraction  library,  displays 
some of the features ofa cytokine gene: in particular, a pre- 
1Abbreviations used in this paper: hlL-17, human IL-17; HVS, Herpesvirus 
saimiri; ORF13, open reading frame 13; mCTLA8, murine cytotoxic  T 
lymphocyte-associated  antigen 8; PGE  2, prostaglandin E2; PI, PMA and 
ionomycin. 
Parts of this work were presented at the 1995 International Congress of 
Immunology on 24-31 July, San Francisco, CA,  at the third Annual 
Conference  of The International  Cytokine  Society  on 12-15 September, 
1995 in Harrogate, UK, and at the Cytokine and Cytokine Receptors 
AACR conference,  on 14-18 October in Bolton Landing, NY. Portions 
of  this work have appeared in abstract form (1995. Cytokine. 7:610). 
dicted hydrophobic NHz-terminal sequence that could cor- 
respond to a signal  peptide  (4)  and the presence in its  3' 
untranslated  region  of AU-rich  repeats  associated  with 
mRNA  instability. Similar motifs have been found previ- 
ously in mRNA  of cytokines, growth factors, and onco- 
genes (5, 6). In addition to a predictable short half-life of  its 
mRNA,  the  expression of mCTLA8 gene  seemed to be 
tightly controlled since the corresponding transcripts could 
only be detected in the original T cell hybridoma after acti- 
vation with PMA and ionomycin (PI) (3). Finally, mCTLA8 
showed 57% homology with the predicted amino acid se- 
quence of the open reading frame 13 (ORF13) of Herpesvi- 
ms saimiri  (HVS) (3), a situation analogous to the presence 
of an IL-10 homolog in Epstein-Barr virus (7). We report 
here the  cloning of the human  counterpart of mCTLA8, 
human  (h)IL-17,  a  cytokine produced  only by activated 
memory T  cells that induces stromal cells to secrete cyto- 
kines  involved  in  inflammatory  and  hematopoietic  pro- 
cesses. 
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Cells and Cell Lines.  PBMC were isolated from the blood of 
healthy  donors,  by  Ficoll-Hypaque centrifugation. The  CD4  + 
cell-enriched population was prepared  from PBMC by negative 
selection  using a cocktail  of mAbs against CD8,  CD40,  CD14, 
and NKH1 antigens and magnetic beads (Dynabeads, Dynal, Olso) 
coated with anti-mouse IgG.  The CD8 + cell-enriched popula- 
tion was prepared by the same method except that anti-CD8 mAb 
was replaced by anti-CD4 mAb. The B cell-enriched population 
was  prepared  by negative selection from normal tonsil using a 
cocktail ofmAbs against CD8, CD4, CD14, and NKH1 antigens. 
The monocyte-enriched population was prepared  from PBMC 
using plastic adherence.  The purity of enriched populations was 
controlled by FACS  |  analysis (Becton Dickinson & Co., Moun- 
tain View, CA). PBMC or enriched populations were cultured in 
P,  PMI medium supplemented with 10% FCS and activated with 
a PI mixture of 5 ng/ml PMA and 3 bg/rnl ionomycin, or 1 I~g/ml 
Con A, or a combination of anti-CD28 and immobilized anti- 
CD3 mAbs (OKT3 plus anti-CD28). Concentrations of hlL-17 
and IFN-7 secreted in the supernatants were detemiined by ELISA, 
and results represent the mean -+ standard deviation of triplicate 
determinations. 
Rheumatoid synoviocytes were isolated from RA patients un- 
dergoing knee or wrist synovectomy and cultured as  described 
before (8). Synovium  pieces were finely minced and digested with 
4 I~g/ml collagenase (Worthington Biochemical Corp., Freehold, 
NJ)  in PBS  Dulbecco's medium (GIBCO BRL,  Gaithersburg, 
MD) for 2-3 h at 37~  After centrifugation, cell suspension was 
resuspended  in  complete  medium made  of a-MEM  (GIBCO 
BRL) with 2 mM L-glutamine, 100 U/ml penicillin, 50 mg/ml 
gentamicin, 20  mM  Hepes  buffer,  and  2%  Ultroser  (GtBCO 
BRL),  and cultured in 150-cm  2 culture flasks (Falcon,  Oxnard, 
CA).  Nonadherent cells were removed and adherent cells were 
trypsinized  at  confluence and passaged.  Synoviocytes  used be- 
tween passages 3 and 8 constituted a homogenous population of 
fibroblast-like  cells, that were negative for  CD2, CD19,  CD14, 
CD45, and HLA-DR expression, as determined by FACScan  |  anal- 
ysis with FITC-conjugated mAbs from Becton Dickinson & Co. 
CHA  and TUMT epithelia/  cell  lines of kidney carcinoma 
were  kindly provided by C.  Bain (Centre L6on B~rard,  Lyon, 
France). MRC-5 human lung fibroblasts were obtained from the 
American Type Culture Collection (Rockville, MD). Bronchial 
epithelial  cells were obtained from F.  Gormond (H6pital Lyon 
Sud, Lyon, France). These three cell lines were cultured in com- 
plete tkPMI 1640 medium (GIBCO BRL), supplemented with 2 
mM L-glutamine,  100 U/ml penicillin, 50 mg/ml gentamicin, 20 
mM Hepes buffer, and 10% heat-inactivated FCS.  Human brain 
endothelial cells, kindly provided by Dr. G.E. Grau (Geneva Uni- 
versity,  Geneva, Switzerland),  were cultured in MEM  (GIBCO 
BRL), supplemented with 10% FCS, 2 mM glutamine, heparin 
(25 U/ml; Sigma Chemical Co., St. Louis, MO), and endothelial 
cell growth supplement (100 ~g/ml, Sigma Chemical Co.). Hu- 
man dermal fibroblasts, kindly provided by Dr. M.T. Zabot (Lab- 
oratoire  de Biochimie, H6pital Debrousse,  Lyon, France),  were 
cultured in complete Ham F-10 medium with 12% FCS. 
Generation of Mouse mAbs against hCTLA8.  Inbred BALB/c 
mice were immunized with three successive intraperitoneal injec- 
tions of Freund's adjuvant (Sigma Chemical Co.) and 100 mg of 
purified hlL-17 obtained from supernatants of hlL-17-transfected 
NS0 cells. Spleens were removed for the fusion 3 d after a final 
i.v. injection of hlL-17. Hybridization was carried  out using the 
nonsecreting myeloma cell line SP2/0-Ag8,  with polyethylene 
glycol 1000 (Sigma Chemical Co.). Hybridoma supematants were 
A 
1  GGCACAAACTCATCCATCCCCAGTTGATTGGAAGAAACAACG 
43  ATGACTCCTGGGAAGACCTCATTGGTGTCACTGCTACTGCTGCTGAGCCTGGAGGCCATA 
1  MetThrProGlyLysThrSerLeuValSerLeuLeuLeuLeuLeuSerLeuGluAlaIle 
103  GTGAAGGCAGGAATCACAATCCCACGAAATCCAGGATGCCCAAATTCTGAGGACAAGAAC 
21  ValLysAlaGlyIleThrIleProArgAsnProGlyCysProAsnSerGluAspLysAsn 
163  TTCCCCCGGACTGTGATGGTCAACCTGAACATCCATAACCGGAATACCAATACCAATCCC 
41  PheProArgThrValMetValAsnLeuAsnIleHisAsnArgAsnThrAsnThrAsnPro 
$ 
223  AAAAGGTCCTCAGATTACTACAACCGATCCACCTCACCTTGGAATCTCCACCGCAATGAG 
61  LysArgSerSerAspTyrTyrAsnArgSerThrSerProTrpAsnLeuHisArgAsnGlu 
283  GACCCTGAGAGATATCCCTCTGTGATCTGGGAGGCAAAGTGCCGCCACTTGGGCTGCATC 
81  AspProGluArgTyrProSerValIleTrpGluAlaLysCysArgHisLeuGiyCysIle 
343  AACGCTGATGGGAACGTGGACTACCACATGAACTCTGTCCCCATCCAGCAAGAGATCCTG 
i01  AsnAlaAspGlyAsnValAspTyrHisMetAsnSerValProIleGlnGlnGluIleLeu 
403  GTCCTGCGCAGGGAGCCTCCACACTGCCCCAACTCCTTCCGGCTCGAGAAGATACTGGTG 
121  ValLeuArgArgGluProProHisCysProAsnSerPheArgLeuGluLysIleLeuVal 
463  TCCGTGGGCTGCACCTGTGTCACCCCGATTGTCCACCATGTGGCCTAAGAGCTCTGGGGA 
141  SerValGlyCysThrCysValThrProIleValHisHisValAlaOCH 
523  GCCCACACTCCCCAAAGCAGTTAGACTATGGAGAGCCGACCCAGCCCCTCAGGAACCCTC 
583  ATCCTTCAAAGACAGCCTCATTTCGGACTAAACTCATTAGAGTTCTTAAGGCAGTTTGTC 
643  CAATTAAAGCTTCAGAGGTAACACTTGGCCAAGATATGAGATCTGAATTACCTTTCCCTC 
703  TTTCCAAGAAGGAAGGTTTGACTGAGTACCAATTTGCTTCTTGTTTACTTTTTTAAGGGC 
763  TTTAAGTTATTTATGTATTTAATATGCCCTGAGATAACTTTGGGGTATAAGATTCCATTT 
823  TAATGAATTACC  TACTTTATTTTGTTTGTCTTTTTAAAGAAGATAAGATTCTGGGCTTGG 
883  GAATTTTATTATTTAAAAGGTAAAACCTGTATTTATTTGAGCTATTTAAGGATCTATTTA 
943  ~GTTTAAGTATTTAGAAAAAGGTGAAAAAGCACTATTATCAGTTCTGCCTAGGTAAATGT 
1003  AAGATAGAATTAAATGGCAGTGCAAAATTTCTGAGTCTTTACAACATACGGATATAGTAT 
1063  TTCCTCCTCTTTGTTTTTAAAAGTTATAACATGGCTGAAAAGAAAGATTAAACCTACTTT 
1123  CATAGTATTAATTTAAATTTTGCAATTTGTTGAGGTTTTACAAGAGATACAGCAAGTCTA 
1183  ACTCTCGGTTCCATTAAACCCTAATAATAAAATCCTTCTGTAATAAA 
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Figure 1.  Nucleotide  sequence of the hlL-17 cDNA and comparison 
of its deduced polypeptide with rolL-17 and OP, FI3 of HVS. hlL-17 
cDNA was cloned as described. (A) Nucleotide and deduced amino  acid 
sequences of the hlL-17 cDNA. The first 23 amino acids constituting  the 
signal peptide appear in italics. The exon sequenced from a genomic li- 
brary starts at nucleotide number 274 (,~), and the eight ATTTA repeats 
are underlined.  The genomic sequence  contains  two polyadenylation  sig- 
nals that are in bold characters. (B) Sequence alignment of proteins en- 
coded by human and murine IL-17 cDNAs and OILF13 ofHVS. Murine 
human and viral (40) protein sequences  were aligned  using the Meg Align 
program (DNASTAR Inc., Madison, WI). Regions  of protein identity  with 
the human sequence are boxed, and the six conserved cysteine residues 
are underlined. The N-glycosylation  site (Asn-X-Ser)  conserved  between 
the three proteins is indicated  by an asterisk. The cDNA sequence data are 
available from EMBL/GenBank/DDBJ  under accession number Z58820. 
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transcripts  are  detected  in  acti- 
vated but  not  resting  CD4 §  T 
cells. PBMC (lanes I and 2), pu- 
rified CD4 + T  cells (71% CD4 +, 
8%  CD8 §  6%  CD14  +,  7% 
CD20+; lanes  3 and 4), purified 
CD8 + T  cells  (70%  CD8 +,  3% 
CD4 +, 2% CD14 §  11% CD20+; 
lanes  5  and  6),  purified B  cells 
(93%  CD19 §  6%  CD4 +,  l% 
CD8 +,  0% CD14+; lanes  7 and 
8) and purified monocytes (73% 
CD14 +, 15% CD20 +, 0% CD4 +, 
0% CD8+; lanes 9 and 10) were 
activated (P/)  or not (-) for 4 h 
with  a  mixture  of  5  ng  ml  -~ 
PMA and 3 p,g m1-1 ionomycin. 
Total  RNAs  were  analyzed  on 
Northern blot with a 32p-labeled 
hlL-17 probe.  (B) Upon activa- 
tion with PI, expression  of hiL- 
l7 mRNA was  restricted to the 
CD4+CD45RO memory T cells 
subset.  Blots  of  hlL-17  RT- 
PCR products obtained after 25 
cycles of amplification from PI- 
activated  (P/)  and  nonactivated 
(-)  peripheral  CD8 +  T  cell- 
enriched population (lanes I and 
2),  tonsillar  CD4+CD45RO + 
(92%  CD4 +,  2%  CD8 +,  2% 
CD19 +, 2% CD14+; lanes 3 and 
4)  and CD4+CD45RA + T  cells 
(90%  CD4 +,  2%  CD8 +,  2% 
CD19 +, 2% CD14+; lanes 5 and 
6) were hybridized with the hiL- 
l7  probe  and  autoradiographed 
for 5 h. The expected size of the 
PCR  product  was  468  bp.  (C) 
Human  hlL-17  is a  N-glycosy- 
lated dinaer. Purified 125I-labeled 
hlL-17  was  digested  with  en- 
doglycosidase-F  (lanes  2  and  4) 
or not (lanes 1 and 3) before mi- 
gration  on  reduced  and  nonre- 
duced  SDS-PAGE.  (D)  Meta- 
bolically  labeled  natural  hlL-17 
secreted  by  activated  CD4 +  T 
cells  (lane  1)  and  recombinant 
hlL-17  produced  by transfected 
NS0 cells (lane 2) appear similar 
upon SDS-PAGE. 
harvested after 6 d, incubated on hlL-17-transfected COS-7 cells 
coated in 96-well  plates for 30  rain at  37~  Antibody binding 
was then revealed with peroxidase-conjugated sheep anti-mouse 
IgG  (Biosys,  Compi~gne,  France)  at a  1:200 dilution in 2% hu- 
man serum/PBS for 1 h  at room temperature.  Positive hybrido- 
mas were  cloned by a  limiting dilution method,  expanded,  and 
produced in ascites from pristane-treated BALB/c mice. After so- 
dium sulphate precipitation of ascites, the mAbs were purified by 
anion-exchange chromatography on a Zephyr-D silicium column 
(IBF Sepracor, ViUeneuve, France). 
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Cloning of hlL-17.  A  human genomic library (Clontech, Palo 
Alto,  CA)  was screened using the mCTLA8  cDNA as  described 
previously  (3).  For  the  cDNA  library,  PBMC  (106/ml)  were 
stimulated  for  4  h  with  PI  before  extraction  of  total  RNAs. 
cDNA  synthesis and cloning was  performed  with a  Superscript 
Plasmid System (GIBCO-BRL) and screened with a probe made 
of the coding region ofhlL-17-terminal exon. 
Northern Blot and Reverse Transcription-PCR Analyses.  CD4 +, 
CD8 +,  B  cells,  and  monocyte-enriched  populations  were  acti- 
vated for 4  h  with PI before  total RNAs  were  extracted by the single-step method (9). Northern blots were performed with 10 Izg 
of total RNA/sample as described  (10).  hIL-17  transcripts  were 
detected with a 32p-labeled probe corresponding to the hlL-17 3' 
exon.  CD4+CD45P, O  and  CD4+CD45RA  cells were  purified 
from tonsil CD4 + cell-enriched populations by negative selection 
using  anti-CD45RO  or anti-CD45RA  antibodies,  respectively. 
For reverse  transcriptase  (P,T)-PCR.,  total  RNAs were  reverse 
transcribed using an oligo-dT primer; half of each cDNA sample 
was PCR. amplified (25  cycles of 1 rain at 95~  2 rain at 50~ 
and 3 min at 72~  using two 24-nucleotides primers that hybrid- 
ize to both  ends  of the  hlL-17  coding region.  To  ensure  equal 
amounts  of total R.NA between samples,  the second half of the 
cDNA samples was PCR amplified under the same conditions us- 
ing  human  [3-actin--specific  primers  (Stratagene  Inc.,  La Jolla, 
CA),  yielding a product  of 661  bp  visualized by ethidium bro- 
mide staining (not shown). The expected size of the hlL-17 PCtL 
product is 468 bp. 
Production and Purification of hlL-17-  and ORF13-encoded Pro- 
teins.  Large  amounts  of  recombinant  hlL-17-  and  ORF13- 
encoded proteins  were  obtained  from  the  supernatants  of NS0 
cells stably  transfected  with the expression plasmid  pEEl2  con- 
taining  the  appropriate  coding  sequences  inserted  between  the 
EcoR1  and Bcll restriction sites.  The secreted hlL-17 was puri- 
fied from the supernatant  by a  three-step  chromatographic  pro- 
cess.  The first step  took advantage  of the presence  of seven His 
Table  1.  Secretion  ofhlL-7 by Human PBMC after Activation 
Cell type  Activation  Time  hlL-17  IFN-y 
h  ng/ml 
PBMC*  None  72  <1.6  ND 
PI  16  6.8  +  0.9  15.4  _+ 0.9 
48  20 +  2.7  16.6  _+  1.4 
72  22.7  +  1.4  16.5  _+  1.7 
Con A  72  6.9 +- 0.2  ND 
OKT3  +  anti-CD28  72  3.8  +  0.3  ND 
CD4 +*  PI  72  8.9  -+ 0.8  ND 
CD8 +*  PI  72  <1.6  ND 
*Donor 1. 
:~Donor 2. 
residues to use a Zn ion affinity column  (11).  Elution from this 
column was performed with a gradient of 20--100 mM Imidazole 
buffer. Fractions containing hlL-17 were then further purified by 
anion  exchange  HPLC  followed by a  third  step  of gel filtration 
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Figure 3.  Biological activities of hlL-17. Recombinant 
hlL-17 increased the secretion oflL-6 (A), IL-8 (C), PGE2 
(E), and G-CSF (G) secretions by rheumatoid  synovial fi- 
broblasts; this effect was completely suppressed in the pres- 
ence of a hlL-17-specific mAb  (B,  D,  F,  and  H).  Cells 
were cultured  for 48 h in various concentrations  of puri- 
fied anti-hlL-17 mAb5 without hlL-17 (open circles), or in 
the presence of 50 ng/ml hlL-17 (closed  circles, B, D, F). In 
H, cells were cultured  for 48 h in culture  medium alone 
(white column), in  50  ng/ml of purified  hlL-17  (dark col- 
umn), or in 50 ng/ml of purified hlL-17 preincubated  for 
30  rain  at  37~  with  1  p.g/ml  of anti-hlL-17  mAb5 
(hatched column). Results represent the mean -+ SD oftripli= 
cate determinations  from one representative experiment. 
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The absence of bacterial endotoxin was verified using the Limu- 
lus Amebocyte Lysate assay  (BioWhittaker, Walkersville, MD). 
OP,  F13-encoded protein was purified by affinity chromatogra- 
phy using the anti-IL-17 mAb5 immobilized to Affigel 10 (Bio- 
P,  ad Laboratories, Hercules, CA). Purified hlL-17 was labeled with 
12sI as previously described (12,  13)  and nontreated or endogly- 
cosidase-F (Boehringer Mannheim, Mannheim, Germany)-digested 
material was submitted to SDS-PAGE under reducing and nonre- 
ducing conditions. A CD4 § cell--enriched cell population was ac- 
tivated with PI for 4 h and then labeled overnight with [3SS]me- 
thionine and [35S]cysteine. Transfected NS0 cells were radiolabeled 
following the same protocol. Secreted proteins were immunopre- 
cipitated with anti-hlL-17 mAb and protein G-Sepharose (Sigma 
Chemical Co.) before comparison by SDS-PAGE. 
Biological Assays.  Synoviocytes, fibroblasts, and epithelial or en- 
dothelial cell lines (104 cells/well) were incubated in 96-well plates 
(Falcon) in a final volume of 250 Ixl of their respective complete 
culture medium. Each cytokine or hlL-17 at indicated concentra- 
tions was added at the onset of the culture. Unless otherwise indi- 
cated, cell-flee supernatants were collected after 48 h, and stored at 
-20~  until cytokine assays. Concentrations oflL-6, IL-8, G-CSF, 
GM-CSF, and prostaglandin E 2 (PGE2) were measured by com- 
mercial two-site sandwich ELISA (Medgenix Diagnostics, Fleu- 
rus,  Belgium or P..&D  Systems Inc.,  Minneapolis, MN).  PGE  2 
levels were measured using a commercial radioimmunoassay (Du- 
Pont NEN, Boston, MA). Biological activities were blocked by 
preincubation at 37~  for 30 rain with 1 txg/ml of the anti-hlL- 
17 mAb5. 
Cocultures of Human Hematopoietic Progenitors with Irradiated Syn- 
oviocytes.  Human  hematopoietic progenitor cells were  isolated 
from cord blood by positive selection using anti-CD34 mAb cou- 
pled to magnetic beads (Miltenyi Biotec, Sunnyvale, CA) as de- 
scribed before (14).  Typically, the purity of CD34 § cells ranged 
from 60 to 90%.  Rheumatoid synovial fibroblasts were seeded at 
a  density of 104  cells/well in  a  96-well plate and  irradiated at 
5,000  rad the day after. Purified hlL-17  or the protein control 
was then added at the same time as the CD34 + cells (104 cells/ 
well). Protein control was a supernatant of mock-transfected NS0 
cells purified by the same procedure as hlL-17. The culture me- 
dium including hlL-17 or the protein control was renewed every 
fifth day. After 8,  12,  and  15  d,  nonadherent  cells were  resus- 
pended from four different wells of each coculture condition and 
viable cells (as judged by trypan blue exclusion) were enumerated 
in a hemacytometer (P, eichert, Buffalo, NY).  Results represent 
the mean  +  standard deviation of duplicate determinations from 
four independent experiments performed with synovial fibroblasts 
and CD34 + cells from different donors. Since the CD34+-enriched 
population also contains nonnegligible amounts of CD34- cells, the 
phenotype of proliferating cells was investigated. For this purpose, 
after 3 d of coculture, nonadherent cells were double-labeled with 
FITC-conjugated anti-CD34  antibody (Immunotech,  Marseille, 
France)  and  Hoechst  reagent  33342  (0.5  ~g/rnl;  Calbiochem- 
Novabiochem Corp., La Jolla, CA) and analyzed by FACS  | 
Results and Discussion 
Cloning ofhlL-17.  The screening of a human  genomic 
library with mCTLA8 cDNA yielded one clone that con- 
tained the 3'-terminal exon and untranslated region ofhlL-17 
(Fig. 1 A). Messenger RNA  analysis with this human probe 
demonstrated  the  expression  of  a  single  1.2-kb  hlL-17 
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Figure 4.  Cooperation between hlL-17 and TNF-et or IFN-~/for the 
secretion of IL-6 and GM-CSF by rheumatoid synoviocytes. These cells 
(104 cells/well)  were incubated with serial  dilutions oflFN-~ (1-100 U/ml) 
or TNF--a (0.1-10 ng/ml) in presence or absence  ofhlL-17 (5 ng/rul). After 
48 h, the levels of IL-6 (A and B) and GM-CSF (C) in the supematants 
were measured by ELISA. Results represent the mean +  SD of triplicate 
determinations from one representative experiment. 
transcript in PBMC activated with PI (Fig. 2 A). Using the 
same probe, three full-length clones encoding hlL-17 were 
isolated from a cDNA library prepared from activated PBMC 
(Fig. 1 A). The OR.F codes for a polypeptide of 155 amino 
acids  that  contains  a  hydrophobic  NH2  terminus,  corre- 
sponding most likely to the signal peptide of secreted pro- 
teins  (4),  and  a  single N-glycosylation site at Ash68.  Like 
the 3'  untranslated region of mCTLA8  and  of several cy- 
tokines,  the  human  sequence  presents eight copies of the 
ATTTA  motif involved in the rapid decay of mRNA  (5, 
6).  The  hlL-17  protein  displays more  homology to  HVS 
OP,.F13  (66%)  than to mCTLA8  (58%), whereas the three 
sequences  show  conservation  of the  six  cysteine residues 
2597  Fossiez et al. and  of the  N-glycosylation  site  (Fig.  1  /3).  Therefore,  the 
amino  acid  sequence  of IL-17 is well  conserved  between 
species. 
hlL- 17 mRNA Is Expressed Mainly in Activated  CD4 + Mem- 
ory T  Cells.  Northern blot analysis could not detect hlL-17 
transcripts in resting PBMC,  CD4 + T  cells,  CD8 §  T  cells, 
B  cells,  monocytes  (Fig.  2  A),  or  in  various  fetal  (heart, 
brain,  lung,  liver,  and  kidney)  or  adult  (heart,  brain,  pla- 
centa, lung, liver, skeletal muscle, kidney, pancreas, spleen, 
thymus,  prostate,  testis,  ovary,  small  intestine,  colon,  and 
PBL)  human  organs  (not  shown).  After  a  4-h  activation 
with  PI,  hlL-17  transcripts  were  found  mainly in  CD4 +- 
activated T  cells (Fig. 2 A). The faint signal observed in ac- 
tivated CD8 § T  cells may be due to residual CD4 + T  cells. 
Activated  B  cells  and  monocytes  did  not  express  hlL-17 
mRNA.  Among activated  CD4 §  T  cells,  the  CD45RO + 
subset was the major source of hlL-17  mRNA  as  demon- 
strated  after  25  cycles  of PCR  amplification  (Fig.  2  /3). 
hlL-17 transcripts could be detected in freshly isolated ton- 
sillar  T  cells  after  35  cycles  of PCR  amplification  (not 
shown).  Thus, hlL-17 transcripts can be detected only in T 
lymphocytes upon activation,  and then mostly, if not only, 
in activated CD4§  + memory T  cells. 
hlL- 17 Is Secreted by Activated  CD4 + T  Cells as a Mixture 
of Homodimeric  Glycosylated  and  Nonglycosylated  Polypeptides. 
Culture  of mouse  NS0  cells  transfected  with  the  plasmid 
expression vector PEEl2  containing the hlL-17 full-length 
cDNA in the presence of [3SS]methionine and [3SS]cysteine 
resulted  in  the  specific  secretion  of two  labeled  proteins 
with apparent molecular weights  of 28,000  and 31,000  on 
SDS-PAGE.  Under  reducing  conditions,  recombinant 
hlL-17  migrated as two compounds of 15 and 22 kD  (Fig. 
2  C).  Digestion  of purified  recombinant  hlL-17  with  en- 
doglycosidase  F yielded the  28-  (nonreducing)  and  15-kD 
(reducing)  species,  suggesting  that  the  higher  molecular 
weight  species represent  N-glycosylated forms  (Fig.  2  C). 
NH2-terminal  amino  acid  sequencing  of the  purified  28- 
and 31-kD bands revealed an identical sequence  starting at 
Gly24.  Thus,  recombinant  hIL-17  is secreted,  after cleav- 
age of a 23-amino  acid signal peptide,  as a mixture  of gly- 
cosylated  and  unglycosylated  covalently  bound  homo- 
dimers.  Immunoprecipitation  with  hIL-17-specific  mAbs 
of 3SS-labeled  supernatants  shows  that  activated  CD4 +  T 
cells and hlL-17  transfected NS0 cells both secreted a mix- 
ture of glycosylated and unglycosylated hIL-17  (Fig.  2  D). 
hlL-17  was  detected  by ELISA  in  the  supernatant  of PI- 
activated PBMC after 16 h  of culture, and its concentration 
reached a plateau after 48 h  (Table  1).  Consistent  with the 
strong hlL-17  mRNA  signal,  supernatants  of H-activated 
CD4 + T  cells or PBMC were found to contain <~22.7 ng/ml 
hlL-17,  indicating  that this  cytokine  was a  major product 
of these activated T  cells  (Table  1).  Con A  or OKT3 plus 
anti-CD28  mAb  activations  both  induced  PBMC  to  se- 
crete  hIL-17,  although  less  than  PI  activation  (Table  1). 
When purified  CD4 + and CD8 + T  cell subsets were acti- 
vated with PI, hlL-17 was detected in supernatants  of acti- 
vated CD4 + T  cells exclusively (Table  1), thus confirming 
at  the  protein  level  that  hlL-17  is  secreted  by  activated 
CD4 + T  cells. 
hlL-17  Induces  Stromal  Cells  to  Secrete  Inflammatory  and 
Hematopoietic  Cytokines.  The properties of purified recom- 
binant  hIL-17 were  assayed on various immune  and  non- 
immune  cell populations,  hlL-17  had  no  major  effect on 
the  proliferation,  cytokine  secretion  (IFN-%  IL-4,  IL-6, 
IL-10),  phenotype  (CD3,  CD4,  CD8),  or  cytotoxicity  of 
total PBMC  or purified CD4 + and  CD8 +  T  cells,  regard- 
less  of whether  these  cells  had  been  activated  with  PHA, 
tetanus toxoid, or IL-2. hlL-17  did not affect the prolifera- 
tion and Ig production  of normal tonsillar B  cells activated 
either through  antigen receptor or through  CD40.  hlL-17 
did not induce proliferation or differentiation of cord blood 
CD34 + hematopoietic  progenitors  cultured  with  or with- 
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out GM-CSF (not shown). In contrast, hlL-17 induced the 
secretion of IL-6, IL-8 ,  PGE  2,  and  G-CSF from primary 
cultures  of synovial fibroblasts (Fig.  3,  A,  C,  E,  and  G). 
The effect of hlL-17 on cytokine and PGE 2 production by 
fibroblasts was  dose dependent with a  half-maximal effect 
at 3  ng/ml,  and a  maximal effect at 20  ng/ml,  suggesting 
high affinity interaction with surface receptors  (Fig. 3, A, 
C,  E,  and  G).  These  effects  were  specific  as  they  were 
blocked by an anti-hlL-17 mAb (Fig. 3,  B,  D,  F, and H). 
The same mAb did not interfere with the IL-113- as well as 
LPS-induced secretion of IL-6 by synoviocytes, thus dem- 
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onstrating  its  binding  specificity  (not  shown).  Purified 
OP,.F13  displays the IL-6- and IL-8-inducing activities of 
hlL-17 and could also be blocked by the anti-hlL-17 neu- 
tralizing mAb (not shown). Thus, hlL-17 (as well as its viral 
counterpart)  turned  out  to  be  a  cytokine-inducing cyto- 
kine. When various combinations of cytokines were tested, 
both TNF-a  and IFN-~/were found to have an additive ef- 
fect on the hlL-17-induced secretion of IL-6 (Fig. 4, A-B). 
Moreover, whereas neither hlL-17  nor TNF-e~ alone had 
any effect on the secretion of GM-CSF, the  combination 
of these two cytokines induced synovial fibroblasts to pro- duce GM-CSF  (Fig.  4  C).  Normal synoviocytes and other 
adherent cells from various human tissues  were tested for 
their capacity to respond to hlL-17. Kidney carcinoma epi- 
thelial  cell lines  (CHA  and TUMT),  primary cultures  of 
skin fibroblasts and brain endothelial cells,  embryonic lung 
fibroblasts  (MKC5),  and  a  bronchial  epithelial  cell  fine 
transformed by SV40, showed an increased secretion oflL-6 
specifically induced by hlL-17 (Fig. 5). Interestingly, hlL-17 
did  not  alter  the  secretion  of these  cytokines  by  blood 
monocytes  (not  shown).  These  observations  suggest  that 
stromal cells from most tissues  would respond similarly to 
the IL-17 produced by activated T  cells. 
Human hlL- 17 Induces Fibroblasts to Support the Growth and 
Differentiation of CD34 + Hematopoietic Progenitors.  As  G-CSF 
(15-17)  and  IL-6  (18,  19)  are  important  hematopoietic 
growth factors, hlL-17 was tested for its effects in coculture 
of CD34 +  hematopoietic  progenitor  cells  and  synovio- 
cytes.  The  latter  are  known  to  support  the  growth  of 
CD34 + progenitor cells as efficiently as primary bone mar- 
row stromal cell lines (20).  As shown in Fig.  6 A, CD34 + 
progenitor  cells  proliferated  moderately  when  cultured 
with irradiated human fibroblasts.  Addition of hlL-17 re- 
sulted in a strong enhancement of this proliferation, with a 
6-10-fold  increase  in  cell number  after  15  d  of culture. 
FACS  |  analysis after 3 d of coculture showed that the only 
cells to enter the cell cycle were CD34 + (Fig. 6 B). Micro- 
scopic examination of cultures demonstrated the presence 
of foci of proliferating round cells after 8 d (Fig. 7 B) and a 
homogenous layer of round  cells  after  12  d  (Fig.  7  D). 
May-Griinwald Giemsa staining showed that over 50% of 
cells generated during 12 d in the presence of hlL-17 had 
the  morphological  characteristics  of mature  neutrophils 
(Fig. 7, F and H). 
Conclusion 
This report describes the molecular cloning, expression 
pattern, biochemical characterizatiofi, and biological activi- 
ties ofhlL-17, a cytokine specifically expressed by activated 
memory T cells that turns on the secretion ofproinflamma- 
tory and  hematopoietic  cytokines by stromal  cells.  After 
hlL-10, hlL-17 is another example of an interleukin that 
has been hijacked by a virus probably as a way to escape the 
host-immune  response.  Interestingly,  as  both  the  IL-8R 
gene cluster and the hlL-17 gene map or/human chromo- 
some 2q31-q35  (3,  21), the present finding of hlL-17 in- 
ducing IL-8 and the  capture of these two genes by HVS 
suggest "dae possibility of a functional relationship between 
IL-81L and hlL-17. 
When compared with IL-2 and IFN-% which are spe- 
cifically produced by both CD4 +  and CD8 +  T  cells,  the 
cellular source of IL-17 appears to be even more restricted, 
inasmuch as only activated CD4 + memory T  cells express 
it. Yet, supernatant of activated blood T  cells contains large 
amounts of  this cytokine (~<20 p~g/ml). It will be important 
to determine whether this secreting population displays  a 
specific phenotype (e.g., Thl vs. Th2) and plays a specific 
role in some pathological conditions. 
In conclusion, the induction of secretion by stromal cells 
of IL-6, IL-8, and PGE  2 but not of IL-1 or TNF, and the 
lack of detectable activity on monocytes suggest a limited 
proinflammatory role of IL-17 in T  cell-driven inflamma- 
tory pathological processes such as psoriasis  or sarcoidosis, 
that is currently being analyzed. Moreover, activated CD4 + 
T  cells  produce hlL-17, which stimulates stromal cells  to 
produce a range of cytokines including IL-6 and G-CSF, 
leading to hematopoiesis of neutrophils in particular.  The 
unique cellular source (activated T  cells) of hlL-17 and its 
capacity to induce the  secretion by stromal cells  of IL-6, 
IL-8, and G-CSF seem tailored to contribute to the induc- 
ible hematopoiesis observed after antigenic stimulation (1, 
22). Thus, activated T  cells may affect hematopoietic pro- 
genitors both directly through the production of IL-3 (23- 
25), IL-4 (26-28), IL-5 (29-31), and GM-CSF (32, 33), as 
well  as  indirectly  through  the  secretion  of hlL-17.  Not 
only could hlL-17 have a long-term effect on hematopoie- 
sis by inducing  G-CSF  production, but,  through the  in- 
duction of IL-6 and  IL-8 release by stromal cells,  it may 
also participate in the triggering of the acute neutrophilia 
(18,  34)  that  permits  a  prompt  nonspecific  immune  re- 
sponse against  infectious agents  (25,  35,  36).  Incidentally, 
the  indirect hematopoietic activity of hlL-17  might par- 
tially explain why removal of T  cells from donor marrow 
leads  to  a  significant  reduction  of engraftment  (37,  38). 
Whether  IL-17  represents  a  redundancy  of the  immune 
system or plays a crucial role in the inflammatory response 
and hematopoiesis will be addressed by the knocking out of 
this gene. 
While  this  work  was  being  submitted  for publication, 
another group also reported the cloning ofhlL-17, the two 
sequences  being  100%  identical  (39).  The  availabilty  of 
highly  purified  recombinant  hlL-17  will  permit  further 
characterization of the full spectrum of their biological ac- 
tivities. 
Figure 7.  Effect  ofhlL-17 on the growth and maturation ofCD34 + cells cocultured  with irradiated synovial  fibroblasts. Cocultures  incubated  for 8 d 
(A, B, E, and F) or 12 d (C, D, G, and/4) with hlL-17 (B, D, F, and/a  o or with the protein control (A, C, E, and G) were observed  under phase contrast 
microscope (￿  (A-D) and after  May-Griinwald  Giemsa  staining. Cells  were identified  as promyelocyte  (PMC), myelocyte  (MC), and polymorphonu- 
clear neutrophil (PMN). 
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